#advanced NSCLC

[mdnewsline1]

Major Breakthrough: Pembrolizumab Shows 5-Year Survival Benefit in NSCLC Patients!

Discover the groundbreaking real-world study on Pembrolizumab for non-small cell lung cancer (NSCLC)! 📊 With a 5-year survival rate of 26.9%, this treatment is changing the game for NSCLC patients. Learn how factors like PD-L1 expression, age, and ECOG-PS impact survival. Read the full analysis now! 🏥🔬

 Read the full study now: https://mdnewsline.com/five-year-survival-in-nsclc-patients-treated-with-first-line-pembrolizumab/

For more insights visit: https://mdnewsline.com/

[usnews23]

Perioperative Immunotherapy: A Promising Advancement in Early NSCLC Treatment

In recent years, the field of oncology has witnessed significant advancements in the treatment of various cancers, including non-small cell lung cancer (NSCLC). One such promising development is the utilization of perioperative immunotherapy, which has shown the potential in improving event-free survival (EFS) for early-stage NSCLC patients. In this comprehensive article, we explore the impact of…

[reasonsforhope]

"Doctors have begun trialling the world’s first mRNA lung cancer vaccine in patients, as experts hailed its “groundbreaking” potential to save thousands of lives.

Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8m deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor.

Now experts are testing a new jab that instructs the body to hunt down and kill cancer cells – then prevents them ever coming back. Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.

The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey.

The UK has six sites, located in England and Wales, with the first UK patient to receive the vaccine having their initial dose on Tuesday [August 20, 2024].

Overall, about 130 patients – from early-stage before surgery or radiotherapy, to late-stage disease or recurrent cancer – will be enrolled to have the jab alongside immunotherapy. About 20 will be from the UK.

The jab uses messenger RNA (mRNA), similar to Covid-19 vaccines, and works by presenting the immune system with tumour markers from NSCLC to prime the body to fight cancer cells expressing these markers.

The aim is to strengthen a person’s immune response to cancer while leaving healthy cells untouched, unlike chemotherapy.

“We are now entering this very exciting new era of mRNA-based immunotherapy clinical trials to investigate the treatment of lung cancer,” said Prof Siow Ming Lee, a consultant medical oncologist at University College London hospitals NHS foundation trust (UCLH), which is leading the trial in the UK.

“It’s simple to deliver, and you can select specific antigens in the cancer cell, and then you target them. This technology is the next big phase of cancer treatment.”

Janusz Racz, 67, from London, was the first person to have the vaccine in the UK. He was diagnosed in May and soon after started chemotherapy and radiotherapy.

The scientist, who specialises in AI, said his profession inspired him to take part in the trial. “I am a scientist too, and I understand that the progress of science – especially in medicine – lies in people agreeing to be involved in such investigations,” he said...

“And also, I can be a part of the team that can provide proof of concept for this new methodology, and the faster it would be implemented across the world, more people will be saved.”

Racz received six consecutive injections five minutes apart over 30 minutes at the National Institute for Health Research UCLH Clinical Research Facility on Tuesday.

Each jab contained different RNA strands. He will get the vaccine every week for six consecutive weeks, and then every three weeks for 54 weeks.

Lee said: “We hope adding this additional treatment will stop the cancer coming back because a lot of time for lung cancer patients, even after surgery and radiation, it does come back.” ...

“We hope to go on to phase 2, phase 3, and then hope it becomes standard of care worldwide and saves lots of lung cancer patients.”

The Guardian revealed in May that thousands of patients in England were to be fast-tracked into groundbreaking trials of cancer vaccines in a revolutionary world-first NHS “matchmaking” scheme to save lives.

Under the scheme, patients who meet the eligibility criteria will gain access to clinical trials for the vaccines that experts say represent a new dawn in cancer treatment."

-via The Guardian, May 30, 2024

[iebpharma1]

Introduction to Osicent 80 mg (Osimertinib)

Osicent 80 mg, the brand name for osimertinib, is an advanced targeted therapy used in the treatment of certain types of non-small cell lung cancer (NSCLC). It falls under the category of epidermal growth factor receptor (EGFR) inhibitors, specifically designed to block the activity of a mutated EGFR protein that is involved in the growth and spread of cancer cells. This medication has revolutionized the treatment of EGFR-mutated lung cancer and is widely utilized for its efficacy in managing advanced stages of cancer, particularly in patients with mutations resistant to other EGFR inhibitors.

Mechanism of Action

Osicent 80 mg (Osimertinib) works by targeting and inhibiting the activity of EGFR that has specific mutations, such as the T790M resistance mutation. EGFR mutations are common in patients with NSCLC, and they often result in the uncontrolled growth of cancer cells. Osimertinib specifically binds to and blocks the EGFR protein, effectively preventing cancer cells from proliferating. By doing so, osimertinib not only helps to stop tumor growth but also promotes cancer cell death, improving the overall prognosis of individuals diagnosed with advanced lung cancer.

Unlike earlier-generation EGFR inhibitors, Osicent 80 mg is designed to be effective against both the common EGFR mutations and the T790M mutation, which often leads to resistance to other treatments. This makes Osicent 80 mg (Osimertinib) an ideal treatment option for patients who have already undergone EGFR-targeted therapy and experienced disease progression.

Indications for Use

Osicent 80 mg is primarily prescribed for patients diagnosed with non-small cell lung cancer who have specific EGFR mutations. The primary indications for the use of Osicent 80 mg include:

First-line treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR mutations: Osicent is used as a first-line therapy in patients who have metastatic NSCLC with exon 19 deletions or exon 21 L858R mutations.

Treatment of NSCLC with T790M mutation: Osicent is highly effective in patients who have acquired resistance to prior EGFR inhibitors due to the T790M mutation, making it a critical option for second-line treatment.

Adjuvant treatment: In some cases, Osicent is prescribed for patients in the adjuvant setting (following surgery) to reduce the risk of cancer recurrence, especially if the tumor has EGFR mutations.

Dosage and Administration

Osicent 80 mg is administered orally, typically once a day, with or without food. The standard dosage is one tablet of 80 mg per day, and the treatment may continue as long as the patient is benefiting from it and can tolerate the medication. In cases of adverse effects, the dose may be adjusted under the guidance of a healthcare provider.

Potential Side Effects

While Osicent 80 mg has been shown to be highly effective in treating NSCLC, like any medication, it can cause side effects. Common side effects include:

Diarrhea: One of the most frequently reported side effects, which can be managed with supportive care.

Rash: A skin rash may develop, often resembling acne, which is common with EGFR inhibitors.

Fatigue: Some patients experience tiredness or weakness during treatment.

Nausea: Although less common, nausea may occur, particularly during the initial phases of treatment.

Interstitial lung disease (ILD): A more serious, though less frequent, side effect is the development of ILD, which causes inflammation in the lungs and requires immediate medical attention.

Most side effects are manageable, and many patients find that the benefits of treatment outweigh the risks, particularly when the drug is effective in controlling cancer growth.

Precautions and Warnings

Before starting Osicent 80 mg, patients should inform their healthcare provider of any pre-existing lung or heart conditions. It is essential to monitor lung function regularly, as some patients may experience pulmonary issues during treatment. Additionally, Osicent can interact with other medications, so it’s crucial to inform the healthcare provider about any other drugs being taken, including over-the-counter medications and supplements.

Pregnant or breastfeeding women should avoid taking Osicent, as it could harm the fetus or infant. The safety of osimertinib in pediatric patients has not been established, so it is generally not recommended for use in children.

Conclusion

Osicent 80 mg (Osimertinib) has significantly changed the landscape of treatment for patients with EGFR-mutated non-small cell lung cancer. As a targeted therapy, it provides a precise and effective option for individuals whose cancer is resistant to other treatments. Its ability to target specific mutations, including the T790M mutation, has made it a vital part of lung cancer management. Patients prescribed Osicent can experience better outcomes, particularly in advanced or metastatic stages of cancer, leading to improved survival rates and quality of life.

As with any cancer treatment, it is crucial for patients to work closely with their healthcare providers to monitor their response to the medication and manage any potential side effects. With continued research and development, the role of Osicent 80 mg in cancer treatment is expected to grow, offering hope to many facing EGFR-mutated non-small cell lung cancer.

[vshospital]

Lung Cancer Treatment in Chennai

Lung cancer treatment in Chennai

Lung cancer treatment in Chennai is witnessing significant advancements, providing hope for thousands of patients diagnosed with this life-threatening disease. Lung cancer, one of the most common cancers globally, affects both men and women. The lungs are a pair of spongy, air-filled organs located on either side of the chest that play a vital role in breathing and oxygenating the body. When cells in the lungs begin to mutate and grow uncontrollably, they form tumors, leading to lung cancer.With a team of experienced oncologists and state-of-the-art facilities, the hospital delivers high-quality care with a              multidisciplinary approach.

What is Lung Cancer?

There are two primary types:

Non-Small Cell Lung Cancer (NSCLC) – This is the most common type and includes subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

Small Cell Lung Cancer (SCLC) – Less common but aggressive, often associated with heavy smoking, and spreads rapidly.

The type and stage of lung cancer play a key role in determining the most suitable treatment plan.

Causes and Risk Factors

Several factors contribute to the development of lung cancer, with smoking being the leading cause. Key risk factors include:

Smoking: Accounts for nearly 85% of lung cancer cases due to carcinogenic substances in cigarettes.

Secondhand Smoke: Continuous exposure increases risk even among non-smokers.

Exposure to Carcinogens: Industrial substances such as asbestos, arsenic, and diesel exhaust.

Family History: A genetic predisposition can increase susceptibility.

Pre-existing Lung Diseases: Conditions like COPD can elevate risk.

Symptoms of Lung Cancer

Recognizing symptoms early can drastically improve treatment outcomes. Common signs include:

Persistent cough that worsens over time

Chest pain while breathing deeply or coughing

Shortness of breath or wheezing

Fatigue and unexplained weight loss

Coughing up blood (hemoptysis)

If any of these symptoms persist, immediate medical evaluation is essential to explore lung cancer treatment in Chennai.

Diagnosis of Lung Cancer       

Early diagnosis is critical for improving survival rates. VS Hospitals in Chennai utilizes advanced diagnostic tools, including:

Chest X-rays and CT Scans: These imaging tests help identify abnormal lung growths or nodules.

Biopsy: Tissue samples are collected via bronchoscopy or needle biopsy to confirm malignancy.

Molecular Testing: Identifies genetic mutations like EGFR or ALK to determine eligibility for targeted therapy.

Early and precise diagnosis not only confirms cancer but also guides effective treatment planning.

Screening for Lung Cancer

Regular screening can save lives, particularly in high-risk individuals like smokers or those with a family history. Modern screening methods available in Chennai include:

Low-dose CT Scan (LDCT): Highly effective in detecting lung cancer at an early stage.

Chest X-rays

Sputum Cytology: Examines mucus for cancer cells.

VS Hospitals offers affordable and reliable screening packages for early lung cancer detection.

Stages of Lung Cancer

Stage 0: Cancer is localized in the inner lining of the lungs.

Stage I: Tumor is small and confined to the lung.

Stage II: Larger tumor with limited lymph node involvement.

Stage III: Advanced tumor affecting lymph nodes and nearby structures.

Stage IV: Cancer has spread (metastasized) to other organs.

The TNM system—Tumor size, Node involvement, and Metastasis—is widely used for staging.

Treatment Options for Lung Cancer in Chennai

Chennai is home to world-class medical institutions, and VS Hospitals stands out for its patient-centric lung cancer treatment programs. Treatment is determined based on cancer type, stage, and patient health.

1. Surgery

Surgical intervention is often the primary choice for early-stage lung cancer. Common procedures include:

Lobectomy – Removal of a lung lobe

Pneumonectomy – Complete lung removal

Segmentectomy – Removal of a lung segment

Minimally invasive options like Video-Assisted Thoracoscopic Surgery (VATS) androbotic-assisted surgery are available at VS Hospitals, ensuring faster recovery and minimal complications.

2. Radiation Therapy

Intensity-Modulated Radiation Therapy (IMRT)

Stereotactic Body Radiation Therapy (SBRT)

These methods allow precise targeting of tumors, preserving healthy lung tissue and enhancing treatment outcomes.

3. Chemotherapy

Chemotherapy uses powerful drugs to kill cancer cells and is typically used in:

Advanced stages

In combination with surgery or radiation

VS Hospitals provides customized chemotherapy plans that reduce side effects and support recovery with additional nutritional and psychological care.

4. Targeted Therapy

This cutting-edge approach targets specific mutations found in cancer cells. Drugs liketyrosine kinase inhibitors are used to block tumor growth with minimal harm to healthy cells. VS Hospitals conducts genetic testing to identify patients suitable for targeted therapy.

5. Immunotherapy

It includes:

Checkpoint inhibitors

Monoclonal antibodies

This therapy is especially useful in advanced cases and is often combined with other treatments for optimal outcomes.

Lung Cancer Treatment Cost in Chennai

 At VS Hospitals, treatment costs vary depending on:

Stage of cancer

Type of therapy (surgery, radiation, etc.)

Length of hospital stay and post-treatment care

Despite being cost-effective, there’s no compromise on quality. Chennai continues to attract patients both domestically and internationally for its advanced yet economical cancer care.

Prognosis and Survival Rate

The prognosis for lung cancer depends largely on the stage at diagnosis and how promptly treatment begins. Key factors that improve prognosis include:

Personalized treatment – Tailored plans for individual genetic profiles

Access to expert care – Experienced oncologists and modern facilities like those at VS Hospitals

For example, localized cancers have survival rates up to 56%, while advanced stages show lower rates, underscoring the importance of early screening.

Prevention Tips

Quitting smoking

Avoiding exposure to secondhand smoke

Reducing contact with radon and industrial chemicals

Using protective gear in workplaces

Conclusion

Chennai, with its world-class healthcare infrastructure, offers exceptional care options. VS Hospitals leads the way with a patient-first approach, offering advanced diagnostic tools, expert oncologists, and personalized treatment options under one roof.

Whether it’s through surgery, chemotherapy, radiation, or immunotherapy, early intervention and comprehensive care are key to improving survival and quality of life. If you or a loved one is seeking the best lung cancer treatment in Chennai, VS Hospitals is a trusted name dedicated to your healing journey. for more details:https://vshospitals.com/causes-of-lung-cancer-in-non-smoker/

[graphicabhi]

PD-1 and PD-L1 Inhibitors Competitive Landscape 2025: Pipeline Progress, Mechanistic Insights, and Clinical Trial Developments | Highlighting Compass Therapeutics, Aurigene Discovery Technologies, RemeGen, and Other Industry Leaders

DelveInsight’s recent analysis reveals a robust global pipeline featuring more than 180 pharmaceutical and biotechnology companies actively developing over 200 therapeutic candidates targeting Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1). This thorough review examines the current state of clinical research, mechanisms of action, modes of administration, and recent developmental updates in this field.

The report, titled “PD-1 and PD-L1 Inhibitors Pipeline Insight, 2025,” delivers an expansive overview of the therapeutic landscape, encompassing drug development progress from preclinical phases through to commercialization. It presents comprehensive profiles of investigational therapies, including their mechanisms, clinical trial activities, regulatory milestones, strategic partnerships, acquisitions, and funding movements.

Get a Free Sample PDF Report to know more about PD-1 and PD-L1 Inhibitors Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape?utm_source=reportstore&utm_medium=promotion&utm_campaign=akpr 

Highlights from the Clinical Trials Landscape for PD-1 and PD-L1 Inhibitors:

Numerous global players are advancing the development of PD-1 and PD-L1 inhibitors. Noteworthy participants include:

Compass Therapeutics

Aurigene Discovery Technologies

RemeGen

Inhibrx

Effector Therapeutics

CytomX Therapeutics

Innovent Biologics

GlaxoSmithKline

Biocad

Genentech

Bristol Myers Squibb

Merck

Key therapeutic candidates currently in the pipeline include:

CTX-8371

CA 327

RC-98

AUR-106

INBRX 105

Tomivosertib

CX-072

IBI 323

Jemperli

BCD-100

TECENTRIQ

Opdivo

KEYTRUDA

These therapies are projected to have a substantial impact on the market trajectory in the coming years.

Recent Clinical Milestones:

May 2025: OmRx Oncology launched a Phase II randomized trial for OX-4224, an oral PD-L1 inhibitor aimed at patients with non-small cell lung cancer. Conducted in India, this study focuses on its use as a second-line monotherapy for patients not previously treated with immune checkpoint inhibitors.

March 2025: Actinium Pharmaceuticals, Inc. began a clinical program to evaluate Actimab-A in combination with KEYTRUDA (pembrolizumab by Merck) or OPDIVO (nivolumab by Bristol Myers Squibb). The aim is to assess whether targeting CD33-positive Myeloid Derived Suppressor Cells can amplify the effectiveness of these established PD-1 inhibitors, which together generated $38.8 billion in revenue in 2024.

January 2025: ImmunityBio, Inc. formed a strategic agreement with BeiGene, Ltd. (transitioning to BeOne Medicines, Ltd.) to conduct the pivotal Phase III ResQ201A-NSCLC study. This trial combines BeiGene’s PD-1 inhibitor tislelizumab with ANKTIVA (nogapendekin alfa inbakicept-pmln) to improve survival in patients with advanced non-small cell lung cancer that has become resistant to checkpoint inhibitor therapy.

Get a Free Sample PDF Report to know more about PD-1 and PD-L1 Inhibitors Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape?utm_source=reportstore&utm_medium=promotion&utm_campaign=akpr 

Understanding PD-1 and PD-L1 Inhibitors:

PD-1 is a checkpoint receptor primarily expressed on T cells, while PD-L1 is its ligand often found on cancer cells. Tumors exploit this pathway to evade immune detection. Inhibiting PD-1 or PD-L1 reinvigorates T cell activity, enabling the immune system to recognize and eliminate cancer cells.

Key Therapeutics in the Development Pipeline:

Compass Therapeutics – CTX-8371

Aurigene Discovery Technologies – CA 327, AUR-106

RemeGen – RC-98

Inhibrx – INBRX 105

Effector Therapeutics – Tomivosertib

CytomX Therapeutics – CX-072

Innovent Biologics – IBI 323

GlaxoSmithKline – Jemperli

Biocad – BCD-100

Genentech – TECENTRIQ

Bristol Myers Squibb – Opdivo

Merck – KEYTRUDA

Pipeline Overview:

DelveInsight’s analysis classifies over 200 drug candidates based on:

Development Stages: Discovery, Preclinical, Phase I, II, and III

Administration Routes

Molecule Types: Small molecules, monoclonal antibodies, etc.

Therapeutic Approach: Monotherapy vs. combination regimens

Leading Industry Contributors:

In addition to the major players mentioned above, the competitive field also includes significant contributions from:

F. Hoffmann-La Roche AG

Sanofi S.A.

Amgen Inc.

AstraZeneca PLC

Pfizer Inc.

Market Outlook and Dynamics:

Drivers: The global rise in cancer prevalence and the increasing use of PD-1 and PD-L1 inhibitors as first-line immunotherapy options.

Challenges: High cost of treatment, risk of immune-related adverse events, and limited access in certain regions remain barriers to market growth.

Scope and Analytical Insights:

Coverage Area: Global

Therapeutic Scope: Both marketed and investigational PD-1 and PD-L1 inhibitors

Program Status: In-depth review of active, inactive, and discontinued development programs

Strategic Analysis: Trends in licensing, collaborations, and investment activities

To explore the full competitive landscape, clinical data, and future market projections, you can download a sample report from DelveInsight: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape?utm_source=reportstore&utm_medium=promotion&utm_campaign=akpr 

Latest Reports:

Adult T-Cell Leukemia Market | Arthralgia Market | Atrial Flutter Market | Attention Deficit Hyperactivity Disorder Market | Bacterial Meningitis Market | Biopsy Devices Market | CART Pipeline | Chlamydia Infections Market | Chronic Neuropathic Pain Market | Convulsive Seizures Market | Coronary Angioplasty Market | Diabetic Gastroparesis Market | Diabetic Nephropathy Market | Electrophysiology Devices Market | Ewing Sarcoma Market | Fabry Disease Market | Gene Therapy In CNS Disorder Market | Glioblastoma Multiforme Market | Graves Disease Market | Hay Fever Conjunctivitis Market | Heart Pump Devices Market | Hydrocephalus Treatment Market | Impetigo Market | Indwelling Catheters Market | Intracranial Hemorrhage Market | Lambert-Eaton Myasthenic Syndrome Market | Lumbar Degenerative Disc Disease Market | Meibomian Gland Dysfunction Market | Metastatic Merkel Cell Carcinoma Market | Metastatic Prostate Cancer Market | Molluscum Contagiosum Market | Myopia Progression Market | NMOSD Market | Nocturia Market | Nonalcoholic Steatohepatitis Market | Nontuberculous Mycobacterial Infections Market

Other Reports Offered By DelveInsight:

About DelveInsight  

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us:

Abhishek kumar

abhishek@delveinsight.com

+14699457679

www.delveinsight.com/consulting

[phillip-e-miles]

Advanced Lung Cancer Care Georgia | Phillip E. Miles

The journey through a lung cancer diagnosis can be daunting, marked by complex decisions and a critical need for cutting-edge treatment. For patients and families in Georgia, accessing the highest caliber of care is paramount. At Curepoint Cancer, we are dedicated to providing Advanced Lung Cancer Care Georgia, combining state-of-the-art technology with compassionate, patient-centered approaches. Guiding this commitment is the profound expertise and visionary leadership of Phillip E. Miles, a respected healthcare leader whose personal experience with cancer deeply informs our mission.

Lung cancer remains a significant health challenge, but advancements in diagnosis and treatment have ushered in a new era of hope. No longer is a diagnosis a definitive endpoint; instead, it's a call to action for personalized, aggressive, and intelligent intervention. Curepoint Cancer is at the forefront of delivering these sophisticated therapies, ensuring that patients in Georgia have access to world-class care close to home.

The Evolution of Advanced Lung Cancer Care

Modern lung cancer treatment is a far cry from the generalized approaches of the past. Today, it leverages a nuanced understanding of the disease's molecular intricacies and the power of precision medicine. At Curepoint Cancer, our approach to advanced lung cancer care encompasses:

Precision Diagnostics and Staging: Accurate diagnosis is the cornerstone of effective treatment. We utilize advanced imaging techniques like PET/CT scans and MRIs, along with comprehensive genomic testing, to identify the specific type and stage of lung cancer (e.g., Non-Small Cell Lung Cancer - NSCLC, Small Cell Lung Cancer - SCLC) and uncover unique genetic mutations or biomarkers. This detailed understanding allows for highly targeted therapies.

Targeted Therapies: These revolutionary drugs specifically attack cancer cells that have particular genetic mutations, minimizing harm to healthy cells. For patients with specific biomarkers, targeted therapies can offer significant benefits, often with fewer side effects than traditional chemotherapy. This personalized medicine approach is a hallmark of advanced care.

Immunotherapy: Harnessing the body's own immune system to fight cancer has transformed lung cancer treatment. Immunotherapy drugs help the immune system recognize and destroy cancer cells that have previously evaded detection. Curepoint Cancer offers the latest immunotherapy options, providing a powerful new weapon against the disease.

Advanced Radiation Therapy: Our facility utilizes cutting-edge radiation technologies, such as Linear Accelerators, to deliver highly precise radiation doses directly to tumors while sparing surrounding healthy tissue. This targeted approach can reduce treatment time, minimize side effects, and improve treatment accuracy.

Minimally Invasive Surgical Options: For eligible patients, our surgical oncology team employs advanced techniques, including minimally invasive procedures, to remove tumors with greater precision, leading to faster recovery times and reduced post-operative discomfort.

Clinical Trials Access: Curepoint Cancer is committed to advancing the field of oncology. We actively participate in and offer access to relevant clinical trials, providing patients with opportunities to benefit from the very latest investigational treatments that are not yet widely available. This ensures patients in Georgia have access to the future of lung cancer care.

Comprehensive Supportive Care: Recognizing that cancer impacts the whole person, our advanced care extends beyond medical treatment. We offer integrated supportive services including nutritional guidance, pain management, counseling, and survivorship programs to enhance quality of life throughout the patient's journey.

Phillip E. Miles and the Curepoint Cancer Philosophy

The vision for Advanced Lung Cancer Care in Georgia at Curepoint Cancer is deeply influenced by the leadership of Phillip E. Miles. As a respected healthcare pioneer and a leukemia survivor himself, Phillip brings a unique and profound understanding of the patient experience. His personal journey instills a powerful sense of empathy and drives the center's commitment to patient-centered care.

Phillip E. Miles emphasizes that effective cancer care goes beyond simply managing the disease; it encompasses robust support, clear communication, and empowering patients with information. His direction ensures that Curepoint Cancer integrates cutting-edge medical advancements with compassionate, personalized attention, making sure every patient receives not just treatment, but comprehensive support designed for their unique needs.

At Curepoint Cancer, under the guidance of Phillip E. Miles, we are redefining Advanced Lung Cancer Care in Georgia. We believe that every patient deserves the most precise, effective, and humane treatment available, offering a genuine path towards improved outcomes and renewed hope.

☎️ (478) 272- 2255

🌐 https://curepointcancer.com

[amolbhanushali]

Is lung cancer curable if caught early?

Lung cancer continues to be the world's most prevalent and dreaded form of cancer, yet better early diagnosis and treatment have shifted the prognosis for many of its victims. It's on the minds of patients, families, and clinicians: "Is lung cancer curable if diagnosed early?" The response is, in short, yes—in the earliest periods, lung cancer is frequently curable if there is proper and timely medical treatment.

This article talks about the determinants of durability, the need for early diagnosis, and how speciality centres such as Dr Bhanushali Hospital and Centre for Lung Surgery can enhance patient outcomes in Thane and elsewhere.

Early Detection and Survival Rates

Survival from lung cancer relies heavily on the diagnosis stage. The American Cancer Society indicates that patients diagnosed with non-small cell lung cancer (NSCLC) that is localised within the lung have a five-year relative survival of 64%. This shows that nearly two-thirds of the localised lung cancer survivors live for five years following treatment.

Other studies, such as those conducted by Mount Sinai researchers, have produced even more encouraging findings: patients with early-stage lung cancer that was found through low-dose CT screening have a remarkable 20-year survival rate of 80%. The rates emphasise the revolutionary impact that early detection makes on long-term survival.

Conversely, the five-year survival rate of lung cancer patients is a paltry 18.6% just because a few, about 16%, are detected early. Over half of lung cancer patients will die within one year of diagnosis when the cancer is diagnosed late, so it is evident how important early detection and screening are.

How Early Detection Works

It is most commonly asymptomatic and will remain undiagnosed if not screened. It is now diagnosed early with low-dose computed tomography (LDCT) scanning to identify small tumours before they become symptomatic or have spread to the rest of the body. It is a new advancement which has come as a saviour to provide surgical tumour removal when the disease is probably curable.

Treatment Options for Early-Stage Lung Cancer

For early-stage lung cancer patients, surgery is the mainstay of treatment. The treatments given below are routine ones:

Lobectomy: Resection of an entire lobe of the lung, the standard for early-stage NSCLC.

Segmentectomy or Wedge Resection: Resection of a minor segment of the lung, appropriate for some patients with small tumours or dysfunctional lungs.

Video-Assisted Thoracoscopic Surgery (VATS): Minimal incision and camera to aid the surgeon, less damaging and quicker healing.

Place of Adjuvant Therapy

In other cases, additional treatment along with surgery, such as chemotherapy or targeted therapy, is also encouraged subsequently as a way of reducing the risk of recurrent disease. Adjuvant chemotherapy has been shown to extend survival in stage II NSCLC, but is less clearly defined in stage I. Scientists who conduct ongoing research continue to refine the treatment regimens, attempting to produce optimal cure rates with minimal toxicity.

Why Specialized Centers are Important

Dr. Bhanushali Hospital and Centre for Lung Surgery in Thane has world-class facilities, advanced surgical procedures, and team-based patient care.

The patients of Dr. Bhanushali Hospital and Centre for Lung Surgery have:

Expert minimally invasive and robotic thoracic surgery

Individualised treatment planning for every patient based on their requirements

Pre- and post-operative care

Free access to the newest diagnostic and therapy equipment

Risk factors and prevention

Although earlier detection is of utmost importance, identification and restriction of risk factors will avoid lung cancer at the initial stage. The primary origin of lung cancer is tobacco smoking, although others include secondhand smoke, radon, asbestos, air pollution, and inherited lung cancer. Quitting smoking and avoidance of carcinogenic exposure are the main requirements for prevention, since these can be modified lifestyle interventions.

Conclusion: Dr Amol Bhanushali and the Future of Lung Cancer Treatment

In short, lung cancer can be cured if detected early through the help of enhanced screening, diagnosis, and treatment. For the people of Thane and its surroundings, Dr. Bhanushali Hospital and Centre for Lung Surgery is a silver lining. The centre is being spearheaded by Dr Amol Bhanushali, a well-known thoracic surgeon who has extensive experience in minimally invasive and robot-assisted procedures.

[prachicmi2]

Advancements in ALK-Positive Lung Cancer Treatment: Targeted Therapies and Improved Patient Outcomes

ALK-positive lung cancer is a distinct subset of non-small cell lung cancer (NSCLC) characterized by the presence of a rearrangement in the anaplastic lymphoma kinase (ALK) gene. This genetic alteration leads to the production of an abnormal ALK protein, which promotes the uncontrolled growth and spread of cancer cells. ALK-positive lung cancer accounts for approximately 3-5% of all NSCLC cases and tends to occur more frequently in younger individuals and non-smokers. The identification of ALK Positive Lung Cancer Treatment rearrangements in lung cancer has revolutionized the approach to treatment, as it has allowed for the development of targeted therapies that specifically address this genetic abnormality. By understanding the unique molecular characteristics of ALK-positive lung cancer, healthcare professionals can now provide more personalized and effective treatment options to patients. Get more insights on,ALK-Positive Lung Cancer Treatment

[vishnudevnb]

Lung Cancer Treatment in Palakkad: Expert Care by Dr Ponraj, Medical Oncologist

Lung cancer remains one of the most challenging cancers worldwide, and in regions like Palakkad, the burden is made heavier by delayed diagnosis and limited awareness. However, with advancements in oncology and the dedicated expertise of specialists like Dr. Ponraj, lung cancer care in Palakkad has evolved into a comprehensive, hope-filled journey.

Why Early Detection Matters

Many patients only discover lung cancer at an advanced stage due to vague or neglected symptoms. Signs such as persistent cough, unexplained weight loss, chest pain, and breathlessness should never be ignored. Dr. Ponraj, a leading medical oncologist in Palakkad, emphasizes the importance of early diagnosis and runs screening and awareness programs to improve early detection rates.

Understanding Lung Cancer

Lung cancer primarily exists in two forms:

Non-Small Cell Lung Cancer (NSCLC) – the most common type, slower-growing

Small Cell Lung Cancer (SCLC) – aggressive and often linked to smoking

Each type requires a unique treatment strategy. Dr. Ponraj uses personalized protocols based on cancer stage, type, and patient profile to achieve the best outcomes.

Leading Risk Factors in Palakkad

The most common contributors to lung cancer in Palakkad include:

Smoking and Secondhand Smoke

Air Pollution from vehicles and industry

Occupational Exposure to dust and chemicals

Family History

To address these risks, Dr. Ponraj focuses on preventive oncology, including public education and environmental awareness.

Advanced Diagnostic Tools

At Thangam Hospital, Dr. Ponraj leads a state-of-the-art diagnostic center offering:

Low-Dose CT Scans for early detection

Bronchoscopy with Biopsy for precise diagnosis

Molecular Testing (EGFR, ALK, KRAS) for personalized therapy

Tumor Board Review for collaborative treatment decisions

This precision-driven system ensures every patient receives a customized lung cancer treatment plan in Palakkad.

Multidisciplinary Treatment Model

Modern lung cancer care needs a team—not just a doctor. Under Dr. Ponraj’s leadership, the Palakkad oncology team includes:

Medical Oncologists for chemotherapy and targeted therapies

Radiation Oncologists for SBRT and palliative care

Thoracic Surgeons for surgical interventions

Pulmonologists for lung function and diagnosis

Palliative Specialists for holistic symptom management

This coordinated, patient-first model ensures timely, integrated care at every step.

Systemic Therapies Offered

Chemotherapy

Refined regimens with better tolerability for all stages of lung cancer.

Targeted Therapy

Drugs like osimertinib or crizotinib used for patients with EGFR/ALK/ROS1 mutations, identified through molecular profiling.

Immunotherapy

Checkpoint inhibitors like pembrolizumab activate the immune system, offering hope to many NSCLC patients.

Each treatment is tailored by Dr. Ponraj, making lung cancer treatment in Palakkad both personalized and progressive.

Supportive and Palliative Care

Lung cancer affects more than just the lungs—it impacts the whole person. That’s why Dr. Ponraj’s approach includes:

Pain Management

Nutritional Support

Emotional Counseling

Survivorship Planning

By addressing every aspect of patient well-being, this holistic model promotes both survival and quality of life.

Why Choose Dr. Ponraj for Lung Cancer Treatment in Palakkad?

15+ Years of Oncology Experience Personalized Treatment Plans based on global protocols Modern Infrastructure at Thangam Hospital Strong Focus on Prevention, Education & Awareness Compassionate, Patient-Centered Philosophy

From the first visit to recovery and beyond, Dr. Ponraj ensures that every lung cancer patient in Palakkad receives the most effective and empathetic care.

FAQs – Lung Cancer Care with Dr. Ponraj

Q: What are the early signs of lung cancer? A: Persistent cough, weight loss, shortness of breath, and chest pain.

Q: Is genetic testing available? A: Yes, advanced molecular profiling is available to guide targeted therapies.

Q: Are virtual consultations offered? A: Yes, online appointments are available for follow-up and second opinions.

Q: How can I book an appointment? A: Call Thangam Hospital or visit our website to schedule your consultation with Dr. Ponraj.

[dopesweetslight]

Lung Cancer Treatment in Varanasi | Pinak Cancer Care Hospital

Lung cancer continues to be a major cause of cancer-related mortality and one of the most frequently diagnosed cancers globally. On the other hand, prompt diagnosis, cutting-edge treatments, and professional care can greatly enhance patient outcomes. Pinak Cancer Care & Superspecialty Hospital is the best cancer hospital in Varanasi if you're looking for lung cancer treatment. It provides top-notch care under the direction of Dr. Pankaj Singh, one of the city's top oncologists.

We'll go over all you need to know about lung cancer in this comprehensive guide, including its signs, causes, available treatments, and the reasons Pinak Cancer Care is the best place to get lung cancer treatment in Eastern Uttar Pradesh and Bihar.

Understanding Lung Cancer

Lung cancer occurs when abnormal cells grow uncontrollably in the tissues of the lungs. There are two major types of lung cancer:

Non-Small Cell Lung Cancer (NSCLC)—The most common type. 

Small Cell Lung Cancer (SCLC)—Often linked to smoking and known to spread faster.

Understanding which type a patient has is critical in determining the right treatment approach.

Common Causes of Lung Cancer

While smoking is the primary cause of lung cancer, several other risk factors contribute to its development:

Exposure to secondhand smoke 

Air pollution 

Family history of lung cancer 

Exposure to asbestos, radon gas, or industrial chemicals 

Previous radiation therapy to the chest

Symptoms of Lung Cancer

Lung cancer may not show symptoms in its early stages. However, common symptoms include:

Persistent cough that doesn’t go away 

Chest pain 

Coughing up blood 

Shortness of breath 

Hoarseness 

Weight loss 

Fatigue 

Frequent respiratory infections (bronchitis or pneumonia)

If you or a loved one experiences these signs, consult an experienced cancer doctor in Varanasi like Dr. Pankaj Singh without delay.

Diagnosis at Pinak Cancer Care: Precise & Prompt

Early detection can significantly increase the chances of successful treatment. At Pinak Cancer Care & Superspecialty Hospital, we use cutting-edge diagnostic tools to identify lung cancer accurately:

Chest X-rays 

CT Scan and PET-CT 

Bronchoscopy 

Biopsy (Needle or Surgical) 

Sputum cytology 

Molecular testing for genetic mutations (like EGFR, ALK)

These tests help us understand the stage and spread of the disease, which forms the basis for designing a personalized treatment plan.

Advanced Lung Cancer Treatment in Varanasi

At Pinak Cancer Care, lung cancer treatment is comprehensive, personalized, and evidence-based. Under the guidance of Dr. Pankaj Singh, one of the most trusted cancer specialists in Varanasi, patients receive multidisciplinary care that includes

1. Surgery

For early-stage lung cancer, surgery may be the best option. Types of surgical procedures include:

Lobectomy (removal of a lung lobe) 

Pneumonectomy (removal of an entire lung) 

Wedge resection (removal of a small part of the lung)

Our expert surgical team ensures precision and safety using minimally invasive techniques where applicable.

2. Chemotherapy

Chemotherapy involves using anti-cancer drugs to destroy cancer cells. It may be used:

Before surgery to shrink tumors 

After surgery to kill the remaining cancer cells 

As a primary treatment in advanced stages

We provide customized chemotherapy plans based on patient tolerance and cancer type, ensuring maximum effectiveness with minimal side effects.

3. Radiation Therapy

This treatment uses high-energy rays to kill cancer cells. It is especially useful in cases where surgery isn’t feasible. Our state-of-the-art linear accelerators ensure targeted treatment with reduced damage to surrounding tissues.

4. Targeted Therapy

Targeted Therapy involves drugs that specifically target genetic mutations in cancer cells (like EGFR, ALK, and ROS1). Molecular profiling is done to determine if targeted therapy is suitable for a patient.

5. Immunotherapy

A groundbreaking advancement in lung cancer care, immunotherapy boosts the body's immune system to fight cancer. It's typically used in advanced cases or when other treatments are ineffective.

Why Choose Pinak Cancer Care for Lung Cancer Treatment in Varanasi?

Here are a few compelling reasons why Pinak Cancer Care & Superspecialty Hospital is the top cancer hospital in Varanasi for lung cancer patients:

i. Best Oncologist in Varanasi

With years of experience and numerous successful cases, Dr. Pankaj Singh is widely regarded as the best cancer doctor in Varanasi, offering unparalleled expertise in lung cancer diagnosis and treatment.

ii. Multidisciplinary Tumor Board

We use a collaborative approach where oncologists, radiologists, surgeons, and pathologists work together to craft the most effective treatment strategy for each patient.

iii. Modern Infrastructure & Technology

From PET-CT scans to advanced radiotherapy machines, our infrastructure is designed to match global cancer care standards.

iv. Patient-Centric Care

We understand the emotional and physical toll of cancer. Our empathetic staff, counselors, and support groups ensure holistic healing.

v. Affordable Lung Cancer Treatment in Varanasi

We believe that quality cancer care should be accessible. Our treatment packages are affordable without compromising quality.

What Sets Dr. Pankaj Singh Apart?

Dr. Singh has earned his reputation not just for his clinical expertise but for his commitment to compassionate care. With international exposure, regular participation in national oncology conferences, and a patient-first philosophy, he has become the go-to lung cancer specialist in Varanasi.

Success Stories from Pinak Cancer Care

Many patients from Varanasi, nearby districts, Bihar, and even Nepal have received successful lung cancer treatment at our hospital. Testimonials often highlight:

Timely diagnosis 

Supportive staff 

Remarkable improvement in quality of life 

Personalized treatment approaches

Preventing Lung Cancer: Tips from Dr. Pankaj Singh

Quit smoking and avoid secondhand smoke 

Test your home for radon 

Eat a healthy diet rich in fruits and vegetables 

Stay physically active 

Regular checkups if you have risk factors

Prevention and early intervention save lives. If you're a smoker above 40, annual lung screening is advisable.

Conclusion

Lung cancer treatment in Varanasi has transformed with the availability of modern facilities and experienced doctors. At Pinak Cancer Care & Superspecialty Hospital, we combine compassionate care with advanced oncology practices to give every patient the best possible chance.

Whether it’s an early-stage tumor or an advanced case, you are not alone in this fight. With Dr. Pankaj Singh, the best oncologist in Varanasi, and our dedicated team, your journey toward recovery begins with trust, care, and expertise.

Book Your Appointment Today

✅Address: Amara, Bypass, Awaleshpur, Akhari, Uttar Pradesh 221005

 Book an appointment 👉: PINAK CANCER CARE & Superspecialty Hospital

 Website 👉:  https://pinakcancerhospital.com/

 Follow us on 👉: Instagram &  Facebook

                               FAQs

Q1. Who is the best doctor for lung cancer in Varanasi?

Dr. Pankaj Singh at Pinak Cancer Care & Superspecialty Hospital is recognized as the best oncologist in Varanasi, known for his expertise and compassionate approach in treating lung cancer.

Q2. How is lung cancer diagnosed?

It is diagnosed using imaging tests like CT scans, chest X-rays, bronchoscopy, and biopsy. Genetic testing may also be done for targeted therapy eligibility.

Q3. What are the treatment options for lung cancer?

Treatment depends on the stage and type of lung cancer. Common options include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy.

Q4. Can lung cancer be cured?

Yes, if detected early, especially in the non-small cell type. Even in advanced stages, treatment can help control the disease and improve quality of life.

Q5. Is treatment affordable at Pinak Cancer Care in Varanasi?

Yes, we aim to provide affordable and accessible cancer treatment while maintaining world-class standards. Financial counseling and support options are also available.

Q6. What makes Pinak Cancer Care the best cancer hospital in Varanasi?

Pinak Cancer Care offers advanced technology, expert doctors like Dr. Pankaj Singh, personalized treatment plans, and comprehensive care under one roof.

[drajettiwari]

Which Types of Cancer Can Be Treated with Chemotherapy?

Chemotherapy is one of the most commonly used and effective treatments for cancer. It involves the use of powerful drugs that destroy rapidly dividing cancer cells. While it can be used alone, chemotherapy is often combined with other treatments like surgery, radiation, or immunotherapy.

1. Brain and Central Nervous System Cancers

Examples: Glioblastoma, medulloblastoma

Chemotherapy is used either after surgery or when radiation isn't effective. Certain drugs can cross the blood-brain barrier to treat brain tumors.

2. Head and Neck Cancers

Examples: Oral cavity, throat (pharynx), larynx, nasal cavity cancers

Often used before or after radiation therapy to shrink tumors and reduce recurrence.

3. Breast Cancer

Chemotherapy is commonly used in early-stage, locally advanced, or metastatic breast cancer.

Given before (neoadjuvant) or after surgery (adjuvant) and especially useful in triple-negative and HER2-positive cancers.

4. Lung Cancer

Examples: Small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC)

SCLC almost always requires chemotherapy. NSCLC may be treated with chemo along with targeted therapy or immunotherapy.

5. Gastrointestinal (GI) Cancers

Examples: Esophageal, stomach, colorectal, pancreatic, liver cancers

Chemotherapy is vital in many GI cancers either before surgery to shrink the tumor or after to prevent recurrence.

6. Leukemia

A blood cancer where chemotherapy is the primary treatment.

Examples: Acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic leukemias

Often requires multiple cycles of chemo and sometimes a stem cell transplant.

7. Lymphoma

Cancer of the lymphatic system.

Examples: Hodgkin lymphoma and non-Hodgkin lymphoma

Usually treated with combination chemotherapy regimens like ABVD, CHOP, etc.

8. Ovarian and Cervical Cancer

Chemotherapy plays a major role in treating advanced-stage ovarian cancer.

In cervical cancer, it's often combined with radiation (chemoradiation).

9. Prostate and Testicular Cancer

Testicular cancer responds extremely well to chemotherapy, often leading to cure even in advanced stages.

In prostate cancer, chemotherapy is used mainly for advanced or resistant cases.

10. Childhood Cancers

Examples: Neuroblastoma, Wilms’ tumor, retinoblastoma, rhabdomyosarcoma

Chemotherapy is the backbone of treatment in many pediatric cancers due to their aggressive growth patterns.

[thelovebudllc]

TTF1 identified as key biomarker for advanced KRAS G12C-mutated non-small cell lung cancer

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), following treatment with the KRAS targeted therapy sotorasib. Results from the study, published today in Nature Medicine, found patients with lung tumors that express low…

[phillip-e-miles]

Advanced Lung Cancer Care Georgia | Phillip E. Miles

A lung cancer diagnosis can be devastating, but for patients in Georgia, the promise of cutting-edge treatment and compassionate support shines brightly at Curepoint Cancer. As a leading cancer treatment center, Curepoint Cancer is dedicated to providing Advanced Lung Cancer Care in Georgia, driven by innovative technologies and a profound commitment to patient well-being, notably influenced by the visionary leadership of Phillip E. Miles.

Phillip E. Miles is far more than a healthcare executive; he is a beacon of empathy and strategic innovation within the medical community. With over 15 years of experience in building and transforming healthcare facilities, including specialized cancer clinics, Mr. Miles brings an unparalleled understanding of operational excellence. However, his most profound impact stems from his personal journey as a leukemia bone marrow survivor. This lived experience has instilled in him a deep commitment to ensuring that every patient receives not just the most effective medical treatments, but also holistic support that addresses their physical, emotional, and psychological needs. His guidance ensures that Curepoint Cancer stands at the forefront of Advanced Lung Cancer Care in Georgia.

At Curepoint Cancer, the approach to lung cancer treatment is characterized by a personalized, multidisciplinary strategy, leveraging the latest advancements in oncology. This ensures that each patient’s unique diagnosis, tumor characteristics, and overall health are meticulously considered to develop the most effective treatment plan. Key aspects of their advanced care include:

Precision Radiation Therapy: Curepoint Cancer utilizes state-of-the-art linear accelerators, such as the Elekta Synergy, for highly targeted radiation delivery. Techniques like Image-Guided Radiation Therapy (IGRT) and Volumetric Modulated Arc Therapy (VMAT) allow for the precise targeting of lung tumors while minimizing exposure to surrounding healthy tissues, including vital organs like the heart and esophagus. This precision is critical for managing side effects and enhancing treatment efficacy, particularly in the complex anatomy of the chest.

Cutting-Edge Diagnostic Capabilities: Early and accurate diagnosis is foundational to successful Advanced Lung Cancer Care. Curepoint adheres to national guidelines for lung cancer screening and employs sophisticated imaging technologies (like advanced CT scans and PET/CT) to precisely locate and stage tumors.

Comprehensive Treatment Modalities: Recognizing that lung cancer treatment often requires a combination of therapies, Curepoint Cancer offers a full spectrum of options, tailored to the specific stage and type of lung cancer (Non-Small Cell Lung Cancer — NSCLC or Small Cell Lung Cancer — SCLC). These include:

Surgery: For early-stage NSCLC, surgical removal of cancerous tissue is a primary option.

Chemotherapy: Used to kill fast-growing cancer cells throughout the body.

Targeted Therapy: These advanced drugs specifically block the growth and spread of cancer cells by targeting unique molecular characteristics of the tumor.

Immunotherapy: Harnessing the body’s own immune system to identify and destroy cancer cells, a revolutionary approach that has significantly improved outcomes for many lung cancer patients.

Multidisciplinary Team Approach: Lung cancer care at Curepoint Cancer involves a collaborative team of board-certified radiation oncologists, medical oncologists, thoracic surgeons, pulmonologists, physicists, dosimetrists, and nurses. This ensures that every aspect of a patient’s care is coordinated and optimized.

Holistic Patient Support: Beyond medical treatments, Curepoint Cancer provides comprehensive support services, including nutritional counseling, psychological support, pain management, and survivorship programs. Phillip E. Miles’s vision extends to digital health solutions, as seen in his involvement with MyHealthAI.org, a HIPAA-compliant platform designed to facilitate secure medical record storage, remote patient monitoring, and communication, further enhancing patient empowerment and support throughout their journey.

For those facing a lung cancer diagnosis in Georgia, Curepoint Cancer, under the empathetic and strategic guidance of Phillip E. Miles, offers a beacon of hope. By combining state-of-the-art technology with a deeply patient-centered philosophy, they are redefining Advanced Lung Cancer Care in Georgia, ensuring that every individual receives the most effective, compassionate, and personalized treatment available to fight this challenging disease.

☎️ (478) 272- 2255

🌐 https://curepointcancer.com